An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring risperidone, schizophrenia, rapidly-dissolving
Eligibility Criteria
Inclusion Criteria: Baseline CGI-Severity score of either "1" (not ill), "2" (very mildly ill), or "3" (mildly ill) Must have been on a stable dose of conventional risperdone tablets (doses of 0.5, 1, 2, 3 or 4 mg/day) to treat their disorder for a minimum of 2 weeks Patients must be able to comply with the study visit schedule and the patient (or a caregiver having frequent contact with the patient) must be able to complete the protocol specified assessments and trial questionnaires Females must be postmenopausal, surgically sterile, or practicing an effective method of birth control, and must have a negative urine pregnancy test pre-study and at the final visit Patient is otherwise healthy on the basis of a pre-trial physical examination and medical history Exclusion Criteria: Patients who cannot take aspartame (an artificial sweetener that is a source of phenylalanine) Currently taking carbamazepine Have a history of neuroleptic malignant syndrome or other serious or unstable medical illnesses Females who is pregnant or breastfeeding Patients who have used an experimental drug or an experimental medical device within 30 days before the start of the trial